-+ 0.00%
-+ 0.00%
-+ 0.00%

MHRA Grants Conditional Marketing Authorisation For Autolus Therapeutics' AUCATZYL For Treatment Of Adult Patients With Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

Benzinga·04/25/2025 16:10:01
Listen to the news
  • UK Medicines and Healthcare products Regulatory Agency (MHRA) authorisation based on FELIX clinical trial of obecabtagene autoleucel in adult patients with r/r B-ALL1
  • AUCATZYL® licensed from MHRA under ‘conditional marketing authorisation', meaning that the MHRA will review new efficacy and safety information at least once every year1

Investors, US and UK National, Medical and Industry media only

LONDON, April 25, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, announces today that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional marketing authorisation for AUCATZYL® (obecabtagene autoleucel) for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL).